https://www.businesswire.com/news/home/20180626006652/en/

RICHMOND, British Columbia & GUILFORD, Conn--(BUSINESS WIRE)--Jun 26, 2018--. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company developing its xB 3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has filed its fourth quarter and annual audited consolidated financial statements and management’s discussion and analysis for the years ended February 28, 2018 and February 28, 2017. All are available under the Company's profile on SEDAR at  www.sedar.com and on the Company's website at  www.bioasis.us/investors/.

On behalf of the Board of Directors of Bioasis Technologies Inc.